Here are five notes from the recommendations:
- The update includes refinement of definitions, reporting terms and grading for cardiovascular adverse events.
- Event adjudication is recommended for complex or rare cardiovascular events such as myocarditis to improve accuracy in classification.
- Trial sites should be educated on recognizing and correctly reporting cardiovascular events. Baseline tests should be used to identify potential adverse events earlier.
- Data collection should be standardized to ensure consistent reporting across trial sites and promote accurate assessment of clinical outcomes.
- Trial sites are encouraged to collaborate with cardiologists as evidence of cancer therapies’ effect on cardiovascular health grows.
Read the full recommendations here.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
